Synthesis of 5-(4-(1H-phenanthro[9,10-d]imidazol-2-yl)benzylidene)thiazolidine-2,4-dione as promising DNA and serum albumin-binding agents and evaluation of antitumor activity

2019 ◽  
Vol 166 ◽  
pp. 267-280 ◽  
Author(s):  
Iqubal Singh ◽  
Richa Rani ◽  
Vijay Luxami ◽  
Kamaldeep Paul
Keyword(s):  
Antitumor Activity ◽  
Serum Albumin ◽  
Albumin Binding ◽  
Binding Agents

scholarly journals Recombinant immunotoxins with albumin-binding domains have long half-lives and high antitumor activity

2018 ◽  
Vol 115 (15) ◽  
pp. E3501-E3508 ◽  
Author(s):  
Junxia Wei ◽  
Tapan K. Bera ◽  
Xiu Fen Liu ◽  
Qi Zhou ◽  
Masanori Onda ◽  
...  
Keyword(s):  
Antitumor Activity ◽  
Serum Albumin ◽  
Cancer Cell ◽  
Half Life ◽  
Cell Uptake ◽  
Mouse Serum ◽  
Albumin Binding ◽  
Protein Toxin ◽  
Furin Cleavage Site ◽  
Recombinant Immunotoxins

Recombinant immunotoxins (RITs) are chimeric proteins consisting of a Fv that binds to a cancer cell and a portion of a protein toxin. One of these, Moxetumomab pasudotox, was shown to be effective in treating patients with some leukemias, where the cells are readily accessible to the RIT. However, their short half-life limits their efficacy in solid tumors, because penetration into the tumors is slow. Albumin and agents bound to albumin have a long half-life in the circulation. To increase the time tumor cells are exposed to RITs, we have produced and evaluated variants that contain either an albumin-binding domain (ABD) from Streptococcus or single-domain antibodies from Llama. We have inserted these ABDs into RITs targeting mesothelin, between the Fv and the furin cleavage site. We find that these proteins can be produced in large amounts, are very cytotoxic to mesothelin-expressing cancer cell lines, and have a high affinity for human or mouse serum albumin. In mice, the RIT containing an ABD from Streptococcus has a longer half-life and higher antitumor activity than the other two. Its half-life in the circulation of mice ranges from 113 to 194 min compared with 13 min for an RIT with no ABD. Cell uptake studies show the RIT enters the target cell bound to serum albumin. We conclude that RITs with improved half-lives and antitumor activity should be evaluated for the treatment of cancer in humans.

The serum albumin-binding region of streptococcal protein G: a bacterial fusion partner with carrier-related properties

1997 ◽  
Vol 201 (1) ◽  
pp. 115-123 ◽  
Author(s):  
Anders Sjölander ◽  
Per-Åke Nygren ◽  
Stefan Ståhl ◽  
Klavs Berzins ◽  
Mathias Uhlén ◽  
...  
Keyword(s):  
Serum Albumin ◽  
Protein G ◽  
Albumin Binding ◽  
Fusion Partner ◽  
Binding Region ◽  
Streptococcal Protein G

Biophysical Insight into Furosemide Binding to Human Serum Albumin: A Study To Unveil Its Impaired Albumin Binding in Uremia

2013 ◽  
Vol 117 (9) ◽  
pp. 2595-2604 ◽  
Author(s):  
Nida Zaidi ◽  
Ejaz Ahmad ◽  
Mohd Rehan ◽  
Gulam Rabbani ◽  
Mohammad R. Ajmal ◽  
...  
Keyword(s):  
Human Serum Albumin ◽  
Serum Albumin ◽  
Human Serum ◽  
Albumin Binding ◽  
Insight Into

Antimicrobial activity of ceftriaxone versus cefotaxime: negative effect of serum albumin binding of ceftriaxone

1994 ◽  
Vol 33 (6) ◽  
pp. 1239-1243 ◽  
Author(s):  
Swapan K. Nath ◽  
Gary A. Foster ◽  
Lionel A. Mandell ◽  
Coleman Rotstein
Keyword(s):  
Antimicrobial Activity ◽  
Serum Albumin ◽  
Albumin Binding ◽  
Negative Effect

Effects of Fatty Acids on Human Serum Albumin Binding Centers

2012 ◽  
Vol 153 (3) ◽  
pp. 323-326 ◽  
Author(s):  
G. E. Dobretsov ◽  
T. I. Syrejshchikova ◽  
N. V. Smolina ◽  
and M. G. Uzbekov
Keyword(s):  
Fatty Acids ◽  
Human Serum Albumin ◽  
Serum Albumin ◽  
Human Serum ◽  
Albumin Binding ◽  
Human Serum Albumin Binding

Chiroptical Properties of Bilirubin-Serum Albumin Binding Sites

Chirality ◽  
2013 ◽  
Vol 25 (4) ◽  
pp. 257-263 ◽  
Author(s):  
Iryna Goncharova ◽  
Sergey Orlov ◽  
Marie Urbanová
Keyword(s):  
Serum Albumin ◽  
Binding Sites ◽  
Albumin Binding ◽  
Chiroptical Properties
Sign in / Sign up

Export Citation Format

Share Document